The Life Sciences team advised Braveheart Bio on its launch with $185 million in Series A financing. Goodwin also advised Braveheart Bio in an exclusive license agreement with Hengrui Pharma.
Braveheart Bio is a late clinical-stage biotechnology company developing novel therapeutics for hypertrophic cardiomyopathy and related conditions. The company is backed by experienced life science investors including Andreessen Horowitz, Forbion, OrbiMed, Enavate Sciences (a platform of Patient Square Capital), and Frazier Life Sciences. Braveheart is advancing BHB-1893 through late-stage clinical development with the goal of establishing a new standard of care.
The deal team for Series A transaction consisted of Kingsley Taft, Katie Hand, Alicia Tschirhart, Maggie Wong, Theo Haboucha, Minji Kim, Ari Kazanjian, Joseph Powers, Ruowen Li, Dan Karelitz, Jacob Osborn, Gozde Guckaya and Carrie Clowney with invaluable assistance from Scott Zilora, Allison Goldsher, Kees van der Kooij, and Teshomech Ayele.
The deal team for the licensing transaction consisted of David Chen, Jennifer Ford, Jo-an Chen, Daniel Karelitz, Erika Pey, Omer Tene, and Arman Oruc with invaluable assistance from Edwin Chan.
For more information on the deal, please read the company press release and see coverage in Endpoints News, Fierce Biotech, and STAT.